Cello Health PLC Directorate Change (0671H)

TIDMCLL

RNS Number : 0671H

Cello Health PLC

12 November 2018

12 November 2018

Cello Health plc

("Cello", the "Company", or the "Group")

Directorate Change

Cello Health plc (AIM: CLL), the global healthcare focused advisory group, is pleased to announce the appointment of Michele Luzi as Non-Executive Director with immediate effect.

Michele is an Advisory Partner of Bain and Company, the global management consultancy, and has served on its global Board. He joined Bain in 1990 and is now reducing his time commitment to the partnership. Since 2010 Michele has served on the Board of Midatech Pharma PLC, a UK Nanotechnology Biotech PLC. Michele is an Italian national.

Mark Scott, Chief Executive, commented: "We are delighted to have Michele on board. He brings with him first-hand experience of growing a global professional service business, as well as a wide knowledge of the healthcare sector. His contribution will be very helpful as we seek to expand Cello's global footprint."

Enquiries:

 
 Cello Group                       020 7812 8460 
 Mark Scott, Chief Executive 
 Mark Bentley, Finance Director 
 
 Cenkos Securities                 0207 397 8900 
 Mark Connelly 
  Harry Hargreaves 
 

Appendix

 
 Full name (age) 
 Michele Luzi (61) 
 Current directorships / partnerships: 
 ASHWICK DEVELOPMENTS LIMITED 
  ASHWICK PROJECTS LIMITED 
  BAINCOMPANY PARTNERS, L.P. 
  JUBILEE FILM PARTNERSHIP LLP 
  MIDATECH PHARMA PLC 
  PROJECT 99 LIMITED 
  ST JAMES MEDIA LLP 
  VIESVI LIMITED 
 Previous directorships / partnerships (in the last 
  five years): 
 MIDATECH LTD 
  RMD TRAFFORD HOUSE 2000 LIMITED 
  RMD TRAFFORD HOUSE LLP 
  YELLOW SKY PUBLISHING LIMITED 
 

As at today's date, Mr Luzi does not hold any ordinary shares in the capital of the Company.

There are no further disclosures to be made pursuant to Schedule 2(g) of the AIM Rules for Companies in respect of Mr Luzi's appointment.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOALLFLLLLLFLIT

(END) Dow Jones Newswires

November 12, 2018 06:30 ET (11:30 GMT)